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Triple-negative breast cancer (TNBC) is highly clinically aggressive and taxol-based chemoresistance remains a big TNBC therapeutic problem to be solved. Verteporfin, a small molecular yes-associated protein 1 (YAP1) inhibitor, is little known as an antitumor drug for TNBC. Our data showed that YAP1 expression was associated with early relapse in tissue samples of patients with TNBC taxol chemoresistance (P < .001). Verteporfin reduced migration and enhanced apoptosis or autophagy of a taxol-resistant MDA-MB-231 cell line in vitro. Knockdown of YAP1 increased epithelial-mesenchymal transition response in a taxol-resistant TNBC cell line. In an in vivo experiment, we found that verteporfin was able to shrink tumor weight and volume and decreased Ki67 expression in a taxol-resistant mouse model.
Our results provide evidence that verteporfin could be a chemosensitizer for TNBC patients with taxol-based treatment.
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of ER and Her-2 expression in TNBC, endocrine and Herceptin (Trastuzumab, Genentech Inc., South San Francisco, CA, USA) therapies are not considered primary treatment and adjuvant chemotherapy such as anthracycline-and taxol-based regimens remain the mainstream treatment.
The majority of TNBC expresses a "basal-like" molecular gene profile, and the BRCA1 pathway contributes to sporadic basal-like breast cancer. To date, tumors respond initially to chemotherapy and targeted agents, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly (ADP-ribose) polymerase (PARP) inhibitors, but there is poor overall survival (OS) of TNBC mainly due to drug acquired resistance. 3 In TNBC treatment, taxol-based regimens have proven to be an important chemotherapy agent. Taxol induces mitosis arrest by stabilizing the spindle microtubules responsible for segregation of duplicated chromosomes to daughter cells. However, the utility of taxol-based chemotherapy in TNBC is limited by the development of drug resistance.
The yes-associated protein (YAP) is inhibited in the Hippo
pathway which is a highly conserved cascade from yeast to humans. YAP1, a member of the YAP family, is a transcriptional coactivator that regulates transcriptional enhancer activator domain (TEAD) transcription factors and promotes cell proliferation.
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Several studies have shown overexpression of YAP 1 in human cancers. 6, [8] [9] [10] Accumulating evidence has suggested oncogenic roles of YAP in cancer progression. 8 Thus, development of pharmacological inhibitors of YAP activity could be potentially valuable in anticancer therapy. Verteporfin (VP) is a small molecular YAP1 inhibitor that disrupts YAP1 conformation and its TEAD-YAP complex. Verteporfin has strong inhibitory effects on cancer cell growth and proliferation. However, the biological significance of anti-YAP therapy in TNBC with taxol chemoresistance is still unclear. In the current study, we reported that YAP1 overexpression is associated with early relapse in TNBC patients, suggesting a potentially significant role of YAP1 in chemoresistance TNBC. We aimed to investigate the functional role of verteporfin in TNBC with taxol resistance in a cell culture system and in an animal model.
| PATIENTS AND ME THODS

| Patient information
One hundred patients were diagnosed with TNBC and treated 
| Cell culture and reagents
| Tissue RNA isolation
Paraffin-embedded tissue samples were cut into 5-10-mm thickness sheets. Total RNA was extracted from the tissue sheets (2-8 sheets)
following the manufacturer's instructions (Bioteck Corporation, Beijing, China).
| Taxol-resistant cell line (MDA-MB-231-TAXO)
MDA-MB-231 cell line was collected and treated with taxol for 
| Animal transplantation tumor experiment
MDA-MB-231 taxol resistance cell line (231R) and 231R stably expressing vector-only and YAP1 shRNA were suspended in PBS solution, and cell count was adjusted to 1 × 10 7 /mL. During every 4 to 6 weeks, nude mice were injected with 100 μL cell suspension.
Then, 1 week after each injection, tumor growth was monitored.
When tumor volume reached 100 mm 3 (calculated using the formula vulaa 2 × b × π/6; b is the length and a is the width in mm), tumor sizes were recorded weekly to control tumor volume within 1500 mm 3 .
Verteprofin was i.p. injected (5 mg/kg body weight) every 2 days for 3 weeks, and the control group was injected with an equal volume of PBS. Tumor volume was measured using magnetic resonance Immunohistochemistry, western blotting, antibodies and reagents, cell viability assay, quantitative real-time PCR, cell immunofluorescence assay and cell apoptosis assay was carried out as described in supplemental materials. Additional materials and methods can be found in Document S1.
| Statistical analysis
Data were analyzed and the significance between groups of treat- Figure 1B) . Furthermore, qPCR analysis showed a significantly higher level of YAP1 gene expression in TNBC patients than in non-TNBC patients (P < .0001) ( Figure 1C ).
This result was confirmed in an immunohistochemistry (IHC) study
where 200 TNBC tissues along with matched controls were subjected to IHC staining for YAP1. Results showed increased nuclear YAP1 staining compared to normal tissues (P < .0001) (representative staining shown in Figure 1D ). Together, the data showed that YAP1 was upregulated in TNBC patients and associated with earlier relapse following taxol-based treatment.
| Upregulation of YAP1 in TNBC cells with taxol resistance in cell culture
In the in vitro experiment, we first established the MDA-MB-231
taxol-resistant cell line (231R, 9.2-fold) and this cell line was then tested in the in vitro experiment ( Figure 2A ). Next, we investigated Figure S1A ). These data suggested that YAP1 was upregulated in TNBC with taxol resistance in vitro.
| Verteporfin regulates cell migration and autophagy in TNBC with taxol resistance
Verteporfin, a small molecule inhibitor of YAP1, was used in the MDA-MB-231 taxol resistance (231R) in vitro study. Survival rate was higher in MDA-MB-231 than in MDA-MB-231/taxo cells (P < .0001) ( Figure 3A ). High inhibition of migration and survival of MDA-MB-231 cells was seen in verteporfin + taxol cells when incubated with taxol, verteporfin or a combination of verteporfin and taxol ( Figure 3B ).
Similar phenotype of migration inhibition was also observed after knockdown of YAP1 protein ( Figure S1B ). In addition, verterporfin or YAP1 siRNA decreased SOX2, CD44 and CD133 expression of autophagy and enhanced E-cadherin and vimentin expression in the epithelial-mesenchymal transition (EMT) pathway ( Figure 3C , Figure   S2A ,B). However, after overexpressing YAP1 protein in 231R cells,
we observed decreased E-cadherin and increased CD133 expression but this phenotype was partially reversed after verteporfin treatment ( Figure S3A ). Taken together, verteporfin may inhibit the migration of TNBC cells and regulate autophagy or EMT of TNBC in vitro.
| Yes-associated protein 1 inhibitor enhances apoptosis in TNBC with taxol resistance in vitro
To investigate the effect of verteporfin treatment on MDA-MB-231
taxol resistance in vitro, we studied TNBC taxol-resistant cells treated with verteporfin. Apoptosis rate was significantly higher in MDA-MB-231/taxo after verteporfin and YAP1 siRNA treatment (P < .0001) ( Figure 4A,B) . Moreover, expression of Bcl2 was inhibited and that of Bax was increased in the verteporfin treatment group ( Figure 4C ). In the in vitro experiment, we also observed decreased BAX and increased Bcl2 expression after knocking down YAP1 protein in 231 R cells ( Figure S3B ). Therefore, verteporfin, the YAP1 inhibitor, significantly enhances apoptosis of TNBC with taxol treatment resistance in vitro.
| Verteporfin sensitizes taxol treatment of TNBC in vivo
Our observations that the YAP1 inhibitor verteporfin enhanced the apoptosis of taxol-resistant TNBC cells encouraged our further 
| D ISCUSS I ON
Yes-associated protein 1 has been studied regarding its function as an oncogene in the promotion of neoplastic transformation such as in hepatocellular carcinoma, colon adenocarcinoma and ovarian carcinoma and others. [11] [12] [13] Because YAP1 function has been linked to neoadjuvant chemotherapy resistance, several drugs have been used to block the activation of YAP1. 14, 15 Verteporfin is a cyclic benzoporphyrin derivative that interrupts YAP/TAZ interaction and thereby inhibits YAP-interacting gene pathways. 15 Other clinical trials tested verteporfin in combination drugs in the setting of pancreatic carcinoma and were proven to be effective. 16 In our study, we generated a TNBC taxol-resistant cell line to investigate anti-YAP1 expression in the reverse of TNBC chemoresistance.
We showed that YAP1 overexpression was associated with early relapse of TNBC patients with taxol chemoresistance. In the in vitro experiments, we showed that knockdown of YAP1 by verteporfin has significant effects on the inhibition of cell migra- In clinical studies, therapy with adjuvant cisplatin or platinumbased agents in TNBC patients has not reached complete pathological remission. 17, 18 Other studies indicate that triple-negative cancers showed insensitivity to taxol-based treatment, which may be due to BRCA1 mutations or TP53 gene mutations. 19, 20 Our study showed that YAP1 overexpression was associated with early relapse of TNBC patients. In addition, we showed that verteporfin, a YAP1 small molecular inhibitor, could serve as a sensitizer in taxol-based chemotherapy in triple-negative cancer in vitro and in vivo. We hypothesize that verteporfin can be considered a potential tailored therapy for TNBC patients in the future. Our results also suggest that YAP1 could be seen as a biomarker for the prognosis of TNBC patients.
F I G U R E 5
Verteporfin reverses taxol resistance of triple-negative breast cancer (TNBC) in vivo. A,B, Tumor volume was measured using magnetic resonance imaging in a 231-taxol resistant (231R) xenograft model. C, Representative images of xenograft tumor are seen. D, Tumor weight was measured in plots. E, Yes-associated protein 1 (YAP1), Ki67 and E-cadherin expression were detected by immunohistochemistry in control, 231-taxol resistance and verteporfin + 231-taxol resistance groups. Scale bars, 100 μm and 5 mm. Data are presented as mean and SEM from three independent experiments. *P < .05. **P < .01. ***P < .001
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